Pharmaceutical News

RSS

Medical marijuana users brace for shortages as Montana’s recreational market opens

More than a year after voters approved legalizing marijuana for recreational use in Montana, anyone older than 21 can now enter a dispensary and buy cannabis. That has medical marijuana user Joylynn Mane Wright worried.

5 Jan 2022

BNT162b2 provides low vaccine responders adequate anti-spike and neutralizing antibodies to prevent SARS-CoV-2

A new study, published on the medRxiv* preprint server, investigated the changes in SARS-CoV-2 antibody levels among HCWs after SARS-CoV-2 vaccination. The study also assessed whether low responders produced sufficient SARS-CoV-2 anti-spike and neutralizing antibodies.

4 Jan 2022

Research demonstrates the safety, feasibility of psilocybin administered at doses of 10mg or 25mg

New research from the Institute of Psychiatry, Psychology, & Neuroscience (IoPPN) at King's College London, in partnership with COMPASS Pathways, has established that psilocybin can be safely administered at doses of either 10mg or 25mg to up to six participants simultaneously.

4 Jan 2022

SARS-CoV-2 mRNA vaccine boosters crucial in maintaining neutralizing antibodies in HCPs

Researchers evaluate the effects of a third dose of the BNT162b2 mRNA vaccine on antibody titers and breakthrough infections in healthcare workers.

4 Jan 2022

Israeli study confirms drop in BNT162b2 efficacy after six months

Researchers determine whether BNT162b2 vaccination has become less efficient in preventing infection over time.

4 Jan 2022

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Researchers analyzed convalescent sera and sera from immunized individuals to demonstrate the evasion of antibodies by the SARS-CoV-2 Omicron variant.

3 Jan 2022

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Researchers combine SARS-CoV-2 spike vaccination with single-cell B-cell receptor sequencing technology to discover neutralizing antibody candidates.

3 Jan 2022

Minimal nAb titers against Omicron in the elderly after 3rd dose

Researchers measured titers of cross-protective neutralizing antibodies against SARS-CoV-2 after they had received a third booster dose.

3 Jan 2022

A reliable assessment of COVID-19 vaccine protection duration

Researchers from the University of North Carolina, University of Washington, and the US Food and Drug Administration propose fitting a Cox model with two time indexes, the event times measured from the start of the study in calendar time and the log hazard for the vaccine effect.

30 Dec 2021

The use of monoclonal antibodies against infectious pathogens

Joshua Tan of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health wrote a review article in the journal DNA and Cell Biology about the role of monoclonal antibodies and briefly described a study on bispecific antibodies that neutralize SARS-CoV-2.

30 Dec 2021

An integrated computational methodology for COVID drug prioritization

Researchers recently published a study in the journal Briefings in Bioinformatics wherein they integrated multiple bioinformatics and cheminformatics-based methods to prioritize drugs for the treatment of COVID-19.

29 Dec 2021

MRNA boosters shown to increase protection against SARS-CoV-2 Omicron

Researchers evaluate vaccine effectiveness against SARS-CoV-2 Omicron and Delta variants.

29 Dec 2021

BNT162b2 booster restores protection following waning of the 2-dose vaccine

Researchers assess the real-world effectiveness of a third booster dose of the Pfizer-BioNTech BNT162b2 vaccine against the initial two-dose regimen.

29 Dec 2021

COVID mRNA vaccines show diminished neutralization responses against Omicron

Researchers report an overview of antibody neutralization by all currently approved vaccines against the SARS-CoV-2 Omicron, Beta, and Delta VOCs.

29 Dec 2021

Combination of rifampicin and resveratrol helps stop dementia, finds study

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Translational Neuroscience, Osaka City University Graduate School of Medicine, had previously shown in a study using mice that the antibiotic rifampicin removes oligomers from the brain and improves cognitive function.

29 Dec 2021

Study demonstrates increased effectiveness of third BNT162b2 dose against SARS-CoV-2 infection and hospitalization

Researchers assess vaccine effectiveness of two and three doses of BNT162b2 against SARS-CoV-2 infections and COVID-19-related hospital admission.

28 Dec 2021

Third BNT162b2 dose effectively neutralizes SARS-CoV-2 Omicron pseudovirus

The findings reveal that the Omicron neutralizing titers induced by the third vaccine dose are comparable to that achieved against the original Wuhan strain (wild-type SARS-CoV-2) by the two-dose regimen. The study is currently available on the medRxiv* preprint server while awaiting peer review.

28 Dec 2021

New report on 1.23 million breakthrough symptomatic SARS-CoV-2 infections by vaccine

A new research letter evaluates whether the estimated vaccine effectiveness changes against infection over time.

28 Dec 2021

Volume of prescribing opioids declined, but the cut was not uniform across geographic areas

The volume of prescription opioids dispensed from retail pharmacies declined by 21% from 2008 to 2018, but the decline was not uniform across geographic areas, among types of patients or by type of prescriber, according to a new RAND Corporation study.

28 Dec 2021

Researchers report loss of antibody potency against SARS-CoV-2 Omicron variant

Researchers find that vaccine-mediated protection against SARS-CoV-2 is significantly reduced against the Omicron variant.

23 Dec 2021

Pharmaceutical News

Medical marijuana users brace for shortages as Montana’s recreational market opens

BNT162b2 provides low vaccine responders adequate anti-spike and neutralizing antibodies to prevent SARS-CoV-2

Research demonstrates the safety, feasibility of psilocybin administered at doses of 10mg or 25mg

SARS-CoV-2 mRNA vaccine boosters crucial in maintaining neutralizing antibodies in HCPs

Israeli study confirms drop in BNT162b2 efficacy after six months

SARS-CoV-2 Omicron variant highly resistant to vaccine-elicited and therapeutic antibodies

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Minimal nAb titers against Omicron in the elderly after 3rd dose

A reliable assessment of COVID-19 vaccine protection duration

The use of monoclonal antibodies against infectious pathogens

An integrated computational methodology for COVID drug prioritization

MRNA boosters shown to increase protection against SARS-CoV-2 Omicron

BNT162b2 booster restores protection following waning of the 2-dose vaccine

COVID mRNA vaccines show diminished neutralization responses against Omicron

Combination of rifampicin and resveratrol helps stop dementia, finds study

Study demonstrates increased effectiveness of third BNT162b2 dose against SARS-CoV-2 infection and hospitalization

Third BNT162b2 dose effectively neutralizes SARS-CoV-2 Omicron pseudovirus

New report on 1.23 million breakthrough symptomatic SARS-CoV-2 infections by vaccine

Volume of prescribing opioids declined, but the cut was not uniform across geographic areas

Researchers report loss of antibody potency against SARS-CoV-2 Omicron variant

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News